Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy
Loading...
Date
2020
Editors
Journal ISSN
Electronic ISSN
ISBN
Bibliographical data
Publisher
Series
URI (citable link)
DOI (citable link)
International patent number
Link to the license
EU project number
Project
Open Access publication
Collections
Title in another language
Publication type
Journal article
Publication status
Published
Published in
Genes & Immunity ; 21 (2020), 5. - pp. 273-287. - Springer Nature. - ISSN 1466-4879. - eISSN 1476-5470
Abstract
The proteasome is a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells that controls numerous cellular processes through regulated protein degradation. Proteasome inhibitors have significantly improved the survival of multiple myeloma patients. However, clinically approved proteasome inhibitors have failed to show efficacy against solid tumors, neither alone nor in combination with other therapies. Targeting the immunoproteasome with selective inhibitors has been therapeutically effective in preclinical models for several autoimmune diseases and colon cancer. Moreover, immunoproteasome inhibitors prevented the chronic rejection of allogeneic organ transplants. In recent years, it has become apparent that inhibition of one single active center of the proteasome is insufficient to achieve therapeutic benefits. In this review we summarize the latest insights how targeting multiple catalytically active proteasome subunits can interfere with disease progression in autoimmunity, growth of solid tumors, and allograft rejection.
Summary in another language
Subject (DDC)
570 Biosciences, Biology
Keywords
Conference
Review
undefined / . - undefined, undefined. - (undefined; undefined)
Cite This
ISO 690
BASLER, Michael, Marcus GRÖTTRUP, 2020. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy. In: Genes & Immunity. Springer Nature. 21(5), pp. 273-287. ISSN 1466-4879. eISSN 1476-5470. Available under: doi: 10.1038/s41435-020-00109-1BibTex
@article{Basler2020-11Recen-50694, year={2020}, doi={10.1038/s41435-020-00109-1}, title={Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy}, number={5}, volume={21}, issn={1466-4879}, journal={Genes & Immunity}, pages={273--287}, author={Basler, Michael and Gröttrup, Marcus} }
RDF
<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/50694"> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dcterms:available> <dc:language>eng</dc:language> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/50694"/> <dc:creator>Basler, Michael</dc:creator> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dc:creator>Gröttrup, Marcus</dc:creator> <dc:rights>terms-of-use</dc:rights> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/50694/1/Basler_2-cd638k2zvyds2.pdf"/> <dcterms:abstract xml:lang="eng">The proteasome is a multicatalytic protease in the cytosol and nucleus of all eukaryotic cells that controls numerous cellular processes through regulated protein degradation. Proteasome inhibitors have significantly improved the survival of multiple myeloma patients. However, clinically approved proteasome inhibitors have failed to show efficacy against solid tumors, neither alone nor in combination with other therapies. Targeting the immunoproteasome with selective inhibitors has been therapeutically effective in preclinical models for several autoimmune diseases and colon cancer. Moreover, immunoproteasome inhibitors prevented the chronic rejection of allogeneic organ transplants. In recent years, it has become apparent that inhibition of one single active center of the proteasome is insufficient to achieve therapeutic benefits. In this review we summarize the latest insights how targeting multiple catalytically active proteasome subunits can interfere with disease progression in autoimmunity, growth of solid tumors, and allograft rejection.</dcterms:abstract> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/50694/1/Basler_2-cd638k2zvyds2.pdf"/> <dcterms:title>Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy</dcterms:title> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-09-04T09:00:45Z</dc:date> <dc:contributor>Basler, Michael</dc:contributor> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/> <foaf:homepage rdf:resource="http://localhost:8080/"/> <dcterms:issued>2020-11</dcterms:issued> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> </rdf:Description> </rdf:RDF>
Internal note
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Examination date of dissertation
Method of financing
Comment on publication
Alliance license
Corresponding Authors der Uni Konstanz vorhanden
International Co-Authors
Bibliography of Konstanz
Yes
Refereed
Yes